BOT 1.45% 34.0¢ botanix pharmaceuticals ltd

Ann: Half Yearly Report and Accounts, page-43

  1. 985 Posts.
    lightbulb Created with Sketch. 417
    last I looked Qbrexa was floundering. I don’t think it will be much competition. Either the side effects were too bad for people, or it wasn’t marketed properly, or just didn’t work well enough.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.